仙灵骨葆胶囊治疗糖皮质激素性骨质疏松症的临床疗效观察  

Effects of Xianling Gubao capsules(仙灵骨葆胶囊) for the treatment of bone loss induced by glucocorticoid

作　　者：吴剑静[1] 温利平[2] 吴云刚[1] 沈权[1] 韩艳[1] 

机构地区：[1]温州医学院附属第一医院,浙江温州325000 [2]温州医学院附属第二医院

出　　处：《中国骨伤》2009年第3期193-195,共3页China Journal of Orthopaedics and Traumatology

摘　　要：目的:评价仙灵骨葆胶囊对糖皮质激素性骨质疏松症的临床疗效。方法:自2005年6月至2007年8月,将50例骨质疏松患者随机分为治疗组和对照组。在应用糖皮质激素治疗的同时治疗组给予仙灵骨葆胶囊口服,对照组给予骨化三醇与钙尔奇D口服。在治疗前、后评价中医证候积分,应用双能X线吸收法测定腰椎和股骨近端的骨密度,观察有关骨代谢指标,包括血全段甲状旁腺素、骨钙素、血钙、血磷以及尿钙和尿磷的变化及不良反应等。结果:治疗6个月后,两组患者的中医证候积分下降,每组治疗前后比较差异均有统计学意义(P<0.05),而且治疗组较对照组下降明显(P<0.05)。腰椎和股骨近端骨密度均升高,每组治疗前后比较差异有统计学意义(P<0.05),组间比较差异无统计学意义(P>0.05)。两组血骨钙素较治疗前下降(P<0.05),而组间无明显差异。对照组治疗后血钙较治疗前升高(P<0.05),与治疗组治疗后比较差异有统计学意义(P<0.05)。两组患者血全段甲状旁腺素、尿钙和血、尿磷治疗前后及组间比较差异均无统计学意义(P>0.05)。对照组治疗过程中曾出现高钙血症1例。结论:两组药物在防治糖皮质激素所致骨质疏松症方面均有很好的临床效果,但仙灵骨葆胶囊疗效更为显著。Objective：To study the clinical effects of Xianling Gubao capsules （仙灵骨葆胶囊） for the treatment of glucocorticoid-induced osteoporosis. Methods ：From 2005.6 to 2007.8,50 patients with primary glomerulonephritis treated with glucocorticoids were divided into two groups randomly. The treatment group were dealed with Xianling Gubao capsules （仙灵骨葆胶囊）, and the control group with calcitriol and Cahrate D 600. TCM Synrdome integral before and after treatment were estimated. And the bone mineral density （BMD） of lumbar spine and femoral neck was measured by dual-energy X-ray absorptionm etry （DEXA）. Osteocalcin, intact parathyroidhormone （IPTH）, urine excretion of calcium and phosphorus, serum calcium and phosphorus were detected before and after treatment ,and adverse effects were investigated too. Results：TCM Synrdome integral in two groups decresed apparently （P〈0.05） ,which decresed more apparently in the treatment group than that in control group （P〈0.05）. BMD of lumbar spine and femoral neck increased in two groups （P〈0.05）, but there were no statistical deferences between them （P〉0.05）. Serum osteocalcin after treatment reduced significantly in two groups （P〈0.05） compared with pre-treatment, but there were no statistical deferences between the treatment and the control group （P〉0.05）. In the control group, serum calcium after treatment increased significantly （P〈0.05） ,but there were no statistical deferences compared with the treatment group （P〉0.05）. There were no statistical deferences in intact parathyroidhormone, urine excretion of calcium and phosphorus, serum phosphorus in the treatment and the control group before and after therapy. Conclusion：Both the treatment group and the control group have clinical effects in prevention and treatment of GC-induced osteoporosis, but the treatment group has more remarkable therapeutic effect and less adverse effects.

关 键 词：骨密度 糖皮质激素 骨化三醇 骨质疏松 中药疗法 

分 类 号：R286.0[医药卫生—中药学] R681[医药卫生—中医学]